* NextCure Inc NXTC.OQ NXTC.O is expected to show no
change in
quarterly revenue when it reports results on May 4
(estimated).
* Refinitiv's mean analyst estimate for NextCure Inc is for
a
loss of 67 cents per share. For the same quarter last year, the
company reported a loss of 60 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for NextCure
Inc is
$16, above its last closing price of $4.16.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.67 -0.67 -0.61 Beat 9.1
Sep. 30 2021 -0.66 -0.67 -0.65 Beat 2.5
Jun. 30 2021 -0.62 -0.61 -0.65 Missed -6.4
Mar. 31 2021 -0.61 -0.59 -0.60 Missed -2.1
Dec. -0.61 -0.60 -0.54 Beat 9.7
31 2020
Sep. 30 2020 -0.56 -0.57 -0.59 Missed -4.2
Jun. 30 2020 -0.51 -0.50 -0.53 Missed -5.8
Mar. 31 2020 -0.44 -0.44 0.33 Beat 174.5
This summary was machine generated May 2 at 16:28 GMT. All
figures in US dollars unless otherwise stated